SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Makers Laboratories - Quaterly Results

13 Feb 2024 Evaluate
The revenue zoomed 5.12% to Rs. 111.69 millions for the quarter ended December 2023 as compared to Rs. 106.25 millions during the corresponding quarter last year.The Net Loss for the quarter ended December 2023 is Rs. -19.46 millions as compared to Net Loss of Rs. -25.70 millions of corresponding quarter ended December 2022 Operating profit Margin for the quarter ended December 2023 improved to -9.94% as compared to -17.11% of corresponding quarter ended December 2022


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 111.69 106.25 5.12 376.36 317.04 18.71 425.47 523.76 -18.77
Other Income 1.22 1.35 -9.63 10.04 9.57 4.91 11.37 8.48 34.08
PBIDT -9.94 -17.11 -41.91 -26.17 -29.99 -12.74 -29.97 38.97 -176.91
Interest 4.19 4.03 3.97 11.72 10.99 6.64 13.81 16.75 -17.55
PBDT -14.13 -21.14 -33.16 -37.89 -40.98 -7.54 -43.78 22.22 -297.03
Depreciation 6.83 6.64 2.86 20.32 17.44 16.51 23.99 19.07 25.80
PBT -20.96 -27.78 -24.55 -58.21 -58.42 -0.36 -67.77 3.15 -2251.43
TAX -1.50 -2.08 -27.88 -4.27 -2.86 49.30 -4.15 1.41 -394.33
Deferred Tax -1.50 -2.08 -27.88 -4.27 -2.86 49.30 -4.30 1.08 -498.15
PAT -19.46 -25.70 -24.28 -53.94 -55.56 -2.92 -63.62 1.74 -3756.32
Equity 59.00 59.00 0.00 59.00 59.00 0.00 59.00 49.17 19.99
PBIDTM(%) -8.90 -16.10 -44.73 -6.95 -9.46 -26.49 -7.04 7.44 -194.67

Makers Laboratories Share Price

155.80 -4.35 (-2.72%)
13-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.20
Cipla 1211.30
Zydus Lifesciences 923.10
Lupin 2312.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×